Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study
Background: Transarterial chemoembolization (TACE) is reserved for the treatment of intermediate hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer stage B); however, it can also be utilized as a neoadjuvant treatment prior to surgical resection in resectable HCC cases. This study aimed t...
Main Authors: | Pipit Burasakarn, Sermsak Hongjinda, Anuparp Thienhiran, Nichaphat Phancharoenkit, Pusit Fuengfoo |
---|---|
Format: | Article |
Language: | English |
Published: |
Society of Gastrointestinal Intervention
2023-10-01
|
Series: | International Journal of Gastrointestinal Intervention |
Subjects: | |
Online Access: | https://www.ijgii.org/journal/view.html?doi=10.18528/ijgii230025 |
Similar Items
-
Analysis of preoperative risk factors for early recurrence after curative pancreatoduodenectomy for resectable pancreatic adenocarcinoma
by: Burasakarn Pipit, et al.
Published: (2022-06-01) -
Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.
by: Ilirian Laçi, et al.
Published: (2022-07-01) -
Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma
by: You-Bin Wang, et al.
Published: (2023-09-01) -
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01) -
Survival Benefit of Transarterial Chemoembolization for Hepatocellular Carcinoma
by: Waqas Ahmad, et al.
Published: (2020-06-01)